榮暉控股(08213.HK)成立合營公司從事口腔護理產品的開發及銷售
格隆匯1月27日丨榮暉控股(08213.HK)公吿,於2022年1月27日,公司間接非全資附屬公司華胤生物科技與中科有康生物科技及科宏生物科技訂立投資合作協議,據此,(其中包括)華胤生物科技、中科有康生物科技及科宏生物科技同意成立合營公司,華胤生物科技的注資總額為人民幣1500萬元。
於合營公司成立後,其由華胤生物科技、中科有康生物科技及科宏生物科技分別擁有51%、45%及4%。合營公司擬於中國深圳設立。待先決條件獲達成後,預期合營公司將主要從事口腔護理產品的開發及銷售。
為實現本集團收入多元化及提升競爭力,集團已自2020年起進軍醫療保健市場,成功打造業務發展新增長點。預期合營公司將專注於(其中包括)口腔護理產品(包括但不限於牙膏)的開發及銷售。口腔護理產品的消費羣體龐大且增長迅速,隨着人們健康意識的不斷提高及消費習慣的改變,口腔護理越來越受到消費者的重視。根據中國國家統計局的數據,規模較大牙膏企業的收入及利潤於2016年至2019年持續增長,增長趨勢顯著。此外,受審美需求及牙齒健康問題的推動,牙膏市場上的功能性高端牙膏越來越多。董事認為,集團可藉此趨勢拓展醫療保健業務,以把握不斷增加的商機。
透過訂立投資合作協議,集團將能夠引進可提供長遠策略支持、專業知識及技術的長期業務夥伴,從而促進集團業務的可持續穩定發展,同時透過過與合營公司合作伙伴(為醫療保健及生物技術行業公司)的合作,增強集團的競爭優勢,進一步鞏固其於醫療保健行業的市場。成立合營公司亦使公司能夠進一步擴大投資規模,從而增加集團的投資收益以及對股東的回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.